Recent advances in migraine treatment include the development of calcitonin gene-related peptide (CGRP) inhibitors, a novel class of medications specifically designed to target migraines. Additionally, non-invasive neuromodulation devices, such as transcranial magnetic stimulation (TMS), have shown promising results in reducing migraine frequency and severity.